Physician profile
Guy C Asher
NPI 1396731212
$3,204.64
in general payments reported to CMS, 2019-2025
18 companies · $349 in 2025
The $349 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $711 · 2020: $237 · 2021: $358 · 2022: $584 · 2023: $338 · 2024: $629 · 2025: $349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,311 · Education: $5.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,310.69 |
| Education | $5.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $592.06 | 2019-2025 | Farxiga, Lokelma, Brilinta |
| Fresenius USA Marketing, INC. | $438.23 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $405.15 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $339.47 | 2019-2025 | Jynarque |
| Akebia Therapeutics INC | $317.98 | 2019-2024 | Vafseo |
| Vifor Pharma, INC. | $312.14 | 2019-2025 | Veltassa |
| Amgen INC. | $160.41 | 2019-2025 | Krystexxa, Tavneos |
| Opko Pharmaceuticals, LLC | $156.60 | 2019-2020 | |
| Horizon Therapeutics Plc | $75.31 | 2020-2023 | Krystexxa |
| Calliditas Therapeutics US INC. | $69.79 | 2023-2024 | Tarpeyo |
| Travere Therapeutics, INC. | $63.22 | 2022-2025 | Thiola |
| Alexion Pharmaceuticals, INC. | $60.52 | 2019-2025 | Ultomiris |
| Mallinckrodt Hospital Products INC. | $60.40 | 2022-2023 | Acthar |
| Glaxosmithkline, LLC. | $44.91 | 2022-2023 | Jesduvroq |
| Daiichi Sankyo INC. | $34.53 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $30.61 | 2024 | |
| Lilly USA, LLC | $27.69 | 2024-2025 | Jardiance |
| Ardelyx, INC. | $15.62 | 2024 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guy Asher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.